Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Age ≥18 years at diagnosis of brain metastases.
Eastern Cooperative Oncology Group (ECOG) Performance Score of <2.
Participants must have a biopsy-proven solid malignancy (histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site) with intracranial lesions radiographically consistent with or pathologically proven to be brain metastases.
Patients who have undergone prior systemic therapy are eligible.
Metastases from hematological malignancy, or central nervous system malignancy.
Patients whose malignancy is being treated with curative intent.
Leptomeningeal metastases.
Contraindication to MRI imaging with contrast.